In recent years, accumulating evidence supports the importance of microRNAs in liver physiology and disease; however, few studies have examined the involvement of these noncoding genes in chemical hepatocarcinogenesis. Here, we examined the liver microRNA profile of male Fischer rats exposed through their diet to genotoxic (2-acetylaminofluorene) and epigenetic (phenobarbital, diethylhexylphthalate, methapyrilene HCL, monuron, and chlorendic acid) chemical hepatocarcinogens, as well as to non-hepatocarcinogenic treatments (benzophenone, and diethylthiourea) for 3 months. The effects of these treatments on liver pathology, plasma clinical parameters, and liver mRNAs were also determined. All hepatocarcinogens affected the expression of liver mRNAs, while the hepatic microRNA profiles were associated with the mode of action of the chemical treatments and corresponded to chemical carcinogenicity. The three nuclear receptor-activating chemicals (phenobarbital, benzophenone, and diethylhexylphthalate) were characterized by the highly correlated induction of the miR-200a/200b/429, which is involved in protecting the epithelial status of cells and of the miR-96/182 clusters. The four non-nuclear receptor-activating hepatocarcinogens were characterized by the early, persistent induction of miR-34, which was associated with DNA damage and oxidative stress in vivo and in vitro. Repression of this microRNA in a hepatoma cell line led to increased cell growth; thus, miR-34a could act to block abnormal cell proliferation in cells exposed to DNA damage or oxidative stress. This study supports the proposal that hepatic microRNA profiles could assist in the earlier evaluation and identification of hepatocarcinogens, especially those acting by epigenetic mechanisms.
The liver is a frequent target for toxicity induced by exogenous chemicals due to the metabolizing activities of hepatocytes and the high concentrations of orally ingested chemicals passing to it directly from the gastrointestinal tract (Hardisty and Brix, 2005) . Exogenous chemicals can drive carcinogenesis by a variety of mechanisms (Hernández et al., 2009; Irigaray and Belpomme, 2010) . DNA-damaging chemicals drive carcinogenesis by causing detrimental mutations of cancer genes.
Conversely, non-DNA reactive chemicals do not damage DNA, but rather drive carcinogenesis by more subtle, epigenetic mechanisms (Boobis et al., 2009) , including the induction of oxidative stress, of cycles of necrosis/regeneration, or by disrupting physiological mitosis and/or apoptosis (Hernández et al., 2009; Irigaray and Belpomme, 2010) . Oxidative stress can damage DNA and proteins through the generated free radicals, as well as disturbing cellular signaling. Cytotoxic chemicals cause cycles of necrosis/regeneration, which promote the growth of neoplastic lesions, the eventual depletion of telomeres, and the release of proinflammatory chemokines and cytokines. Disruption of the normal proliferation and apoptosis balance drives tumor promotion by favoring the expansion of mutated cells.
To protect human health, novel chemicals are evaluated for potential carcinogenicity. DNA-reactive chemicals can be readily and reliably detected by a number of in vitro and in vivo tests, such as mutation, chromosomal aberration, and micronucleus assays (Boobis et al., 2009) . In contrast, no reliable assays exist for the identification of human epigenetic carcinogens. This situation arises due to the limited understanding of the molecular, biochemical, and cellular events that are associated with epigenetic carcinogenesis. Consequently, risk assessment for carcinogenicity of chemicals (the rodent bioassay) is currently a laborious, complicated, time-consuming, animal demanding, and costly process (Boobis et al., 2009) . Moreover, this current benchmark for the evaluation of novel chemicals is often irrelevant to humans due to species differences and the high doses that are used (Boobis et al., 2009) . The development of better assays for epigenetic hepatocarcinogens is dependent on an improved understanding of the molecular events associated with this type of chemical.
MicroRNAs (miRNAs) are a family of evolutionary conserved noncoding RNAs that posttranscriptionally regulate their target genes. In recent years, accumulating evidence supports the importance of liver miRNAs in physiology and disease, including cancer (Bala et al., 2009) . Numerous studies have shown altered expression in liver tumors (Hou et al., 2011; Pineau et al., 2010) ; However, so far only a handful of toxicological sciences 128(2), 532-543 (2012) doi:10.1093/toxsci/kfs170 Advance Access publication May 12, 2012 studies have examined the function of miRNAs during chemical hepatocarcinogenesis, and these have been mostly restricted to a single chemical treatment Moffat et al., 2007; Pogribny et al., 2009; Shah et al., 2007; Yauk et al., 2010) . In this study, the effects of subchronic treatment with a variety of chemical treatments were examined in parallel. Chemical treatments were chosen to represent diverse modes of action (MOA), carcinogenic potential, and effects on the liver. For each chemical, its maximum tolerated dose or a carcinogenic dose, as reported in the literature, for this rat strain was used. Phenobarbital (PB) and benzophenone (BP) belong to the PB-type class of compounds that activate the constitutive androstane receptor (CAR) (Chhabra, 2000; Kodama and Negishi, 2006) , whereas diethylhexylphthalate (DEHP) activates the peroxisome proliferator-activated receptor alpha (PPARα) (Lapinskas et al., 2005) . Chronic activation of these receptors drives hepatocarcinogenesis in rodents by disrupting proliferation/apoptosis of initiated cells (Lake, 2010) . All three chemicals cause the induction of hepatic tumors in mice, but only DEHP has the same effect in this rat strain (Butler, 1978; NTP TR-217, 1982; NTP TR-533, 2006) . Methapyrilene HCl (MP HCL) is an hepatotoxic hepatocarcinogen that promotes cancer by inducing necrosis/regeneration (Lijinsky, 1984) . The potent hepatocarcinogen 2-acetyl aminofluorene (2-AAF) was the only genotoxic chemical used here, while also having additional promoting activity (Neuman et al., 1997) . Also included in this study were two non-DNA-damaging hepatocarcinogens with unknown MOA, monuron (MON) (NTP TR-266, 1988 ) and chlorendic acid (Chl. Ac) (NTP TR-304, 1987) . As a control chemical, diethylthiourea (DETU) was included, a kidney carcinogen with few reported liver effects (NTP TR-149, 1979) . We found that assessing the hepatic miRNAome is a potentially useful avenue for assessing the mechanisms and carcinogenic potential of chemical treatments.
MATERIALS AND METHODS
Animal study. All the chemicals used in this study were purchased from Sigma-Aldrich (Dorset, U.K.). Male Fischer (F344) rats were obtained from Harlan Olac (The Netherlands) and left to acclimatize for 7 days prior to the commencement of the treatments. Animals were then randomly assigned to cages and treatment. The chemical treatments used in this study are summarized in Table 1 . Nine-week old rats were continually exposed to each chemical in their diet (N = 5 animals per group) for a period of up to 3 months. The animal studies were performed in accordance with the U.K. "Animals Scientific Procedures Act" under controlled lighting (12 h light cycles), humidity (30-70%), air flow (15 changes per hour), and temperature (22 ± 3°C) conditions. Rats were given access to main water and diet ad libitum. Exposure of the animals to the chemicals was verified by chemical analysis of the diets and daily monitoring of food intake. At the end of the study, animals were killed by an overdose of anesthetic (halothane Ph.Eur.Vapor) followed by exsanguination. Liver tissue was obtained from the animals immediately upon sacrifice, snap frozen, and stored at −80°C until needed.
Evaluation of histopathology and measurement of clinical parameters. For histopathology, liver sections were taken from the three main liver lobes, embedded in paraffin wax, sectioned at 5 µm, stained with hematoxylin and eosin, and examined by light microscopy. For clinical chemistry, plasma was collected and the levels of glutamate dehydrogenase, alanine aminotransferase, and aspartate aminotransferase were measured. mRNA microarray analysis. Profiling of liver mRNAs was performed as previously described (Waterman et al., 2010) , using the Affymetrix Rat Expression RG-230 v2 GeneChips (Affymetrix, Buckinghamshire, U.K.). miRNA microarray analysis. For miRNA analysis, total RNA was extracted from the left lateral liver lobes using TRIzol (Invitrogen, Paisley, U.K.) following the manufacturer's instructions. The RNA was deemed suitable for microarray analysis if it had a A260:A280 ratio above 2.0 (as determined by NanoDrop ND-1000) and an RNA integrity number greater than eight (as determined using an Agilent Bioanalyzer). For miRNA profiling, three to five liver samples from each group were examined. Profiling of miRNA expression was performed using the Agilent miRNA microarray platform (Agilent, Stockport, U.K.). The microarray slides contained 350 rat miRNAs that were included in the Sanger 10.1 database. The slides were viewed using an Agilent scanner (G2505B), and the data were collected using the Agilent Feature Extraction v.10.1 software. The miRNA hybridization signals were threshold to 1, log2 transformed, and normalized to the 75th percentile in GeneSpring GX 11.0. miRNAs that were not flagged as present by the Agilent feature extraction software in at least 50% of the samples in any treatment group were filtered out from further analysis. For six liver samples (three control animals and three PB-treated animals), the whole process from RNA extraction onwards was performed twice to assess the reproducibility of the generated microarray data (control and PB technical replicates).
Quantitative real-time PCR analysis. For mRNAs, reverse transcription was performed using the High Capacity cDNA RT kit (Applied Biosystems, Warrington, U.K.). The generated cDNA was amplified using the TaqMan 2X Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems), with each PCR reaction performed in triplicate. The quantitative real-time PCR (qPCR) data were analyzed in the ABI 7500 Real-time PCR System (Applied Biosystems). The comparative Ct Method (ΔΔC T method) was used to quantify miRNA expression. Calibration was based on the expression of the 18s rRNA TaqMan. For miRNAs, total RNA was reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). Mature miRNA TaqMan assays were purchased from Applied Biosystems. Quantification was performed as per manufacturer's instructions using 18s rRNA or snoRNA as the calibrator gene. Ogiso et al. (1985) Note. *Nodular hyperplasia.
MIRNA AND CHEMICAL HEPATOCARCINOGENESIS serum. Recombinant human transforming growth factor beta 1(TGF-β1) was purchased from RD (Abingdon, U.K.) and used as described previously (Caja et al., 2007) . Etoposide and hydrogen peroxide were obtained from Sigma-Aldrich.
Statistical analysis. Student's t-test and ANOVA were used to test for statistical significance. Deregulated mRNAs were identified as those with p < 0.05 (t-test from control) and more than 1.5-fold change from control. Overexpressed gene ontology (GO) categories were identified as those with p < 0.01 within GeneSpring GX 11.0. One-way ANOVA with BenjaminiHochberg multiple testing correction followed by Tukey's honestly significant difference (HSD) post hoc test were used to identify differentially expressed miRNAs. To identify predictive miRNA signatures, the Prediction Analysis of Microarrays (PAM) software was used (Tibshrani et al., 2002) .
RESULTS

Effects of Chemical Treatments on Liver Pathology, Clinical
Chemistry, and mRNA Profiles
To certify that the treatments had the expected hepatic effects, we evaluated plasma clinical parameters, liver pathology and biochemistry, and liver mRNA expression of the treated animals (Tables 2 and 3 ). The nuclear receptor activators (PB, BP, and DEHP) resulted in hepatic hypertrophy and significant increases in adjusted liver weight (Table 2 ). PB and BP treatments also induced cyp2b1 (11.5-fold and 9.5-fold from control, respectively), which is a defining characteristic of CAR activation (Lake, 2009) . Similarly, DEHP caused changes in the expression of mRNAs that are characteristic of PPARα activation, such as the induction of cyp4a1 (4.7-fold from control) and an enrichment of genes involved in lipid metabolism (Lake, 2009; Lapinskas et al., 2005) (Table 3 ).
In accordance with its known cytotoxic properties, MP HCL caused the largest increases in the plasma levels of three markers of hepatotoxicity (glutamate dehydrogenase, aspartate aminotransferase, and alkaline aminotransferase) ( Table 2) ; it was the only compound for which evidence of necrosis/apoptosis was found upon histopathological examination (Table 2) ; and MP HCL together with 2-AAF was the only treatment that resulted in an enrichment of the cell cycle GO group, affecting a number of cell cycle genes (Tables 3 and 4) . 2-AAF was also the only compound to cause an enrichment of the programmed cell death GO group (Tables 3 and 5) , although no increase in liver necrosis/apoptosis was detected (Table 2) .
MON was the only compound besides the nuclear receptor activators to induce a significant, albeit small, increase in adjusted liver weight at 3 months (113% control), as well as to induce minimal liver vacuolation (Table 2 ). Both MON and Chl. Ac caused an enrichment of mRNAs involved in the oxidation-reduction GO, while also affecting a number of genes involved in lipid metabolism (Table 3 ). The non-hepatocarcinogen DETU had few effects on the examined liver parameters (Table 2) , affected fewer mRNAs (Table 3) , 12.4 ± 1.3 12.5 ± 1.6 15.5 ± 2.1** 11.7 ± 1.2 18.7 ± 2.1** 15.8 ± 0.8 10.6 ± 0.5 12.5 ± 0.5 12.1 ± 0.8 Adjusted liver weight 11.6 11.7 14.7* 13.1* 19.9* 14.7* 11.5 11. 9 Note. Liver weights were analyzed by analysis of covariance on final body weight. For the other measurements, ANOVA was used. CON is control group; for the other treatments, see abbreviations in Table 1 . Mean values and standard deviations are shown, n = 3-5 animals per group. *p < 0.05; **p < 0.01. and did not result in the enrichment of any GO group (Table 3) . Overall, chemical treatments had the expected hepatic effects after subchronic treatment (Chhabra, 2000; Lake, 2009; Lapinskas et al., 2005; Neuman et al., 1997; NTP TR-149, 1979; NTP TR-266, 1988; NTP TR-304, 1987) .
Effects of Chemical Treatments on the Liver miRNAome at 3 Months
We next used a microarray platform to examine the effects of the chemical treatments on the liver miRNAome. Box plot analysis demonstrated comparable distributions of the microarray samples (Fig. 1A) , whereas two sets of technical replicates revealed a very strong correlation of miRNA expressions (Fig. 1B) , confirming the reliability and reproducibility of the microarray data. As independent validation, the expression levels of five miRNAs were determined by qPCR and found to be highly correlated to their expression changes calculated by microarrays (Fig. 1C) . Therefore, the microarray platform that was utilized here proved to be reliable and reproducible.
With one-way ANOVA and Bonferroni-Holm multiple testing correction, 21 miRNAs had significantly altered expression in animals treated with one or more compounds compared with control animals after 3 months (Table 6 ). Importantly, all the hepatocarcinogens had effects on the liver miRNAome, whereas no hepatic miRNAs displayed significant deregulation compared with control following treatment with the non-hepatocarcinogen chemical DETU. The deregulated miRNAs included several belonging to the same genomic clusters or families, which as expected showed highly correlated expression in response to the chemical treatments (Pearson's correlations for miR-200b-miR200a, r = 0.98; miR-200b-miR-429, r = 0.96; miR-96-miR-182, r = 0.96; miR-99a-miR-100, r = 0.98; and miR-29a-miR-29c, Note. Significantly deregulated probes were identified as those with a p value < 0.05 and more than 1.5-fold change by a t-test between treated and control groups at 90 days. Values shown are the mean fold change between control and chemical-treated animals as determined by microarray analysis of mRNAs that were affected by MP HCL and 2-AAF treatment and are involved in the "cell cycle" GO category. ns, not significant. Note. Significantly deregulated probes were identified as those with a p value < 0.05 and more than 1.5-fold change by a t-test between treated and control groups at 90 days. Values shown are the mean fold change between control and chemical-treated animals as determined by microarray analysis of mRNAs that were affected by 2-AAF treatment and are involved in the "programmed cell death" GO category. r = 0.95). Importantly, the clustering of the samples based on the differentially expressed miRNAs follows a logical order, suggesting that hepatic miRNA profiles reflect the MOA of the chemicals (Fig. 1D) . DETU, the chemical with the least effects on the liver, is associated with the control animals. In a second node, the two PB-type compounds, PB and BP, clustered together. A third node contained the two compounds that had the largest effect on cell cycle at 3 months (MP HCL and 2-AAF). Hepatic miRNA profiles also clustered together the three most potent hepatocarcinogens tested in this study (2-AAF, MP HCL, and Chl. Ac).
It should be noted that the chemical treatments caused both downregulation and upregulation of miRNAs (Table 6 ).
In terms of magnitude, most altered miRNAs were changed between 1.5-and 5-fold from control, similar to the changes observed between hepatocellular carcinoma (HCC) and benign liver tissue (Hou et al., 2011) . Some of the observed miRNA deregulation was specific to a particular compound, for example, the induction of miR-107 by DEHP or miR-139-5p by Chl. Ac. We were particularly interested in identifying miRNAs that were affected by more than one chemical, as these could be involved in a more general adaptive or adverse response to the treatment. Compared with control animals, ten miRNAs had significantly altered expression in the livers of animals treated with two or more chemicals: members of the miR-200a/200b/429 cluster (PB, DEHP, BP, 2-AAF, Chl. It was also observed that there was a significant correlation between the number of mRNA probes and miRNAs that were deregulated compared with control for each treatment (r = 0.74; p < 0.05 Spearman's correlation), indicating that there is an association with the strength of the perturbation induced by chemical treatments on these two gene classes.
In conclusion, our findings demonstrate that chemical hepatocarcinogens affect liver miRNA profiles after long-term treatments; these profiles are associated with the MOA of chemicals, and that a surprisingly consistent set of miRNAs are affected by chemical treatments.
Effect of Nuclear Receptor Activators on Liver miRNAs
The three nuclear receptor activators (PB, BP, and DEHP) had clearly distinct effects on liver pathology, including the induction of hepatomegaly and hypertrophy (Table 2) The two PB-type compounds (PB and BP) are both reported to be mice hepatocarcinogens, and PB is reported to induce hyperplastic foci in the livers of male Fischer rats (Butler, 1978; NTP TR-533, 2006 ). The two compounds have overall very similar effects on the liver miRNAome at 3 months (see significantly deregulated miRNAs for each treatment in Table 6 and clustering in Fig. 1D ), probably reflecting their common MOA. Interestingly, it was observed here that PB and BP could be distinguished at the miRNA level by the repression of miR-221 following BP treatment (Fig. 2C) . Several studies have reported that miR-221 is a liver oncogene, driving hepatocyte proliferation and suppressing apoptosis (Park et al., 2011; Pineau et al., 2010; Sharma et al., 2011) . The repression of miR-221 after BP treatment could therefore contribute to the noncarcinogenicity of BP in these animals compared with PB.
Regulation and Adaptive Functions of the miR-200a/200b/429
Cluster and of miR-34a
The hepatic miRNAs most commonly affected by the tested chemicals were the members of the miR-200a/200b/429 cluster and miR-34a (Figs. 3A and 3B ). miR-200b was not affected by treatment of male Fischer rats for 7 days with 2-AAF or MP HCL (Fig. 3C) , indicating that it is only induced after longer treatments. For miR-34a, a significant induction could be observed in animals treated with 2-AAF or MP HCL from Note. Differentially regulated miRNAs were identified using one-way ANOVA with Bonferroni-Holm multiple testing correction and p < 0.05. For treatment abbreviations, see Table 1 . Values shown are average absolute fold change from control in that treatment. Underlined values are miRNAs with significantly altered expression in livers of treated animals compared with control animals (Tukey's HSD post hoc test p < 0.05).
MIRNA AND CHEMICAL HEPATOCARCINOGENESIS this early time point (Fig. 3D) , indicating that unlike for the miR-200a/200b/429 cluster, its induction is an earlier and persistent effect.
miR-34a and miR-200b are known to be p53-regulated miRNAs (Hermeking, 2010; Kim et al., 2011) . This is in agreement with the pronounced and persistent induction of this miRNA in rats treated with genotoxic 2-AAF. Only 2-AAF treatment resulted in significant induction of a number of p53-regulated genes (e.g., bax, 2.3-fold from control; cdkn1a, 3.7-fold from control; and ccng1 3.3-fold from control). In agreement with this observation, treatment of the rat hepatoma cell line Fao with the DNA-damaging agent etoposide resulted in the induction of both miR-34a and miR-200b (Fig. 4A) .
In contrast, the other three hepatocarcinogens that induce miR-34a are not thought to be DNA-damaging chemicals (Lijinski, 1984; NTP-TR-266; NTP-TR-304) , and hence their effect on the expression of this miRNA is probably occurring by alternative mechanisms. One such mechanism is the induction of oxidative stress, which has been suggested to be involved in the propagation of MP cytotoxicity (Craig et al., 2006) . Accordingly, MP HCL treatment resulted in the induction of three genes (akr7a3, 4.3-fold; srxn1, 1.9-fold; and trib3, 3.4-fold), which have been associated with glutathione depletion . Additionally, for both MON and Chl. Ac, an enrichment of mRNAs involved in the oxidation-reduction process was observed, with this GO category being the only enriched one following treatment with the former chemical (Table 3) . Hence, oxidative stress could be the mechanism linking the induction of miR-34a with these chemical treatments. Importantly, hydrogen peroxide treatment resulted in the induction of miR-34a, but not of miR-200b in Fao rat hepatoma cells, indicating that this miRNA can be induced by oxidative stress (Fig. 4B) .
The miR-200 family inhibits epithelial to mesenchymal transition (EMT), a process that facilitates the acquisition of invasive and metastatic properties in numerous tissues, by promoting the expression of cdh1 (e-cadherin) through repression of the zeb1/zeb2 transcription factors (reviewed in Dykxhoorn, 2010) . However, cdh1 was not among the deregulated mRNAs in the livers of treated animals according to the transcriptomic data (data not shown). To confirm that this miRNA family associates with the regulation of cdh1 in the rat liver, we examined a cellular model whereby treatment of Fao rat hepatoma cells with TGF-β1 results in the downregulation of cdh1 and morphological changes that are reminiscent of EMT (Caja et al., 2007) . As reported (Caja et al., 2007) , TGF-β1 treatment for 48 h resulted in the downregulation of the expression of cdh1 in Fao cells (Fig. 4C) . We found that the downregulation of cdh1 in Fao cells treated with TGF-β1 is also associated with the downregulation of miR-200b (Fig. 4C) , suggesting that the induction of these miRNAs is indeed involved in the regulation of the expression of cdh1 in rat hepatic cells. miR-34a is an established negative regulator of the cell cycle (Hermeking, 2010) . In agreement with this observation, transfection of anti-miR-34a into Fao cells resulted in an increased number of viable cells after 3 days of culture (Fig. 4D) . Transfection of miR-99a, which was also affected by 2-AAF and MP HCL, had no effect on cell growth (Fig. 4D) . The induction of hepatic miR-34a is therefore an early and persistent event that can act to prevent abnormal cell growth due to DNA damage or oxidative stress.
Using Hepatic miRNA Profiles to Identify Hepatocarcinogenic Chemicals
We finally examined whether hepatic miRNA biomarkers or signatures can facilitate the earlier identification of chemical hepatocarcinogens. An important limitation for such an analysis was the relatively small training set of compounds, which is insufficient for the evaluation of sensitivity and specificity of any identified miRNA signatures. Nevertheless, such an analysis can be a preliminary indicator of whether miRNA data can be useful for deriving predictive models using data from a larger training set. For that purpose, we tested the predictive abilities of the set of 10 miRNAs that were significantly affected by two or more of the chemical treatments (Table 6) . We utilized the PAM software within the BRB-array tools developed by Dr Richard Simon and the BRB-ArrayTools Development Team. PAM is a statistical technique that uses a gene signature (classifier) to assign class to samples using the nearest shrunken centroid (Tibshirani et al., 2002) . Using these 10 miRNA signatures, the PAM algorithm could correctly classify all six hepatocarcinogenic treatments, as well as the non-hepatocarcinogen DETU (Figs. 5A and 5B). However, this signature is probably too stringent, as it also classified PB and BP as hepatocarcinogens (Figs. 5A and 5B).
DISCUSSION
An important finding of this study was that all the tested carcinogens affected the expression of hepatic miRNAs at 3 months. In this context, it is important to note that the only two studies in which hepatocarcinogenic chemicals were reported not to affect hepatic miRNAs had examined livers following acute treatments (Moffat et al., 2007; Yauk et al., 2010) , in contrast to the acute treatment with the hepatotoxins, acetaminophen, and carbon tetrachloride, which deregulated miRNAs within 24 h (Fukushima et al., 2007) . Additionally, it has recently been reported that treatment with the genotoxic hepatocarcinogen ethylnitrosourea has minimal effects on liver miRNAs after 1 or 3 days but has much more prominent effects after 14 and 28 days . Together, these observations suggest that liver miRNAs appear to be initially refractory to acute hepatocarcinogenic treatments, although the reason behind this discrepancy is currently unknown. However, the data collected here make it clear that subchronic and chronic chemical treatments eventually induce prominent effects on the liver miRNAome that are discernible well before the appearance of hepatic tumors.
Although some effects of the treatments on the liver miRNAome were chemical specific, a small set of miRNAs was commonly affected by diverse carcinogenic treatments that were examined here. It is noteworthy that this set did not include miRNAs that have been previously strongly associated with HCC, such as miR-122, miR-21, and miR-199a-3p (Hou et al., 2011; Pineau et al., 2010) . These miRNAs may not be important in chemically induced hepatocarcinogenesis, or alternatively they may not be deregulated until the later stages of the disease.
The most commonly chemical-affected hepatic miRNAs at 3 months were members of the miR-200a/200b/429 cluster and miR-34a (Figs. 3A and 3B) . In recent years, numerous studies have reported that the miR-200 family acts as a positive regulator of the expression of cdh1, an important cell-tocell adhesion molecule (reviewed in Dykxhoorn, 2010) . Downregulation of cdh1 is a key event implicated in EMT, a developmental process involved in the acquisition of invasive faculties in liver cancer (Ding et al., 2010; Kim et al., 2011) . We showed here that the miR-200a/200b/429 cluster is downregulated during the induced repression of cdh1 in Fao rat hepatoma cells by TGF-β1. The induction of the miR-200a/200b/429 cluster could be an adaptive response protecting the epithelial state of hepatocytes by sustaining high levels of cdh1 expression.
miR-34a has been reported to be upregulated in HCC (Pineau et al., 2010) , as well as in response to treatment with hepatocarcinogens (Li et al., 2011; Pogribny et al., 2007; Shah et al., 2007) . Here, it was unaffected by the two non-hepatocarcinogenic MIRNA AND CHEMICAL HEPATOCARCINOGENESIS treatments at 3 months, whereas it was significantly induced by all four non-nuclear receptor-activating hepatocarcinogens (Fig. 3B) . This miRNA has widespread effects on the proteome of hepatic cells, resulting in a cell cycle block (Cheng et al., 2010) and has also been reported to be involved in terminating liver regeneration after hepatectomy (Chen et al., 2011) . The in vivo and in vitro findings in this study suggest that this miRNA is involved in the hepatic response to DNA damage and oxidative stress. Paradoxically, we found here that this miRNA was persistently induced by the two chemical treatments that resulted in increased cell cycle at 3 months, MP HCL and 2-AAF (Tables 2-4). One possible explanation of this phenomenon is that the proliferating liver cells are a hepatic subpopulation in which this miRNA is not induced. Alternatively, the proliferative and antiapoptotic effects of these carcinogens may overcome the cell cycle block that is associated with miR-34a activity. Interestingly, the expression of miR-34a is progressively increased in HCC (Pineau et al., 2010) , indicating that hepatic cancer cells can bypass the tumor-suppressive properties of this miRNA.
This study therefore suggests that liver miRNAs have fundamental roles in directing adaptive responses during the early stages of chemical hepatocarcinogenesis (Fig. 6 ). This does not exclude the possibility that other deregulated miRNAs that were identified here may have adverse functions, for example, miR-99a is commonly repressed in HCC (Hou et al., 2011) .
Omics technologies are being pursued as potential methodology that can complement or replace the 2-year rodent bioassay (Blomme et al., 2009; Ellinger-Ziegelbauer et al., 2008) . It has been reported that the mRNA profiles of livers reflect the MOA of the chemicals with which they are treated (Ellinger-Ziegelbauer et al., 2008 ). An important question for this study was whether examination of hepatic miRNA profiles could offer mechanistic information about the tested chemicals. The observations collected here suggest that a similar link exists between chemical mechanisms and hepatic miRNA profiles. First, the tested nuclear receptor activators and non-nuclear receptor activators had clearly distinct miRNA profiles at 3 months of treatment (Correlated induction of miR-200a/200b/429 and miR-96/182 cluster vs. induction of miR-34a). Second, hierarchical clustering analysis demonstrated similar miRNA profiles of two structurally diverse PB-type compounds (PB and BP) and of the chemicals which had the strongest effect on the cell cycle and apoptosis (2-AAF and MP HCL). Third, expression of miRNAs was linked to carcinogenic mechanisms, for example, miR-34a with genotoxicity and oxidative stress. Fourth, PB treatment (induces hyperplastic liver foci) could be discriminated from BP treatment from differential effects on miR-221, a miRNA which is strongly linked with liver cancer development.
Given the observations discussed above, a reasonable hypothesis would be that miRNA biomarkers or signatures can be identified that will facilitate the safety evaluation of chemicals, with due respect to the caveat that only a small number of chemicals were tested here. However, it is important to note that this study supports, as a proof of principle, that miRNA expression contains predictive information. Of the hepatic miRNAs found to be deregulated in this study, miR-34a showed the greatest potential to be a useful biomarker for those chemical hepatocarcinogens that act through the induction of DNA damage or oxidative stress. We also used the PAM software to evaluate the predictive powers of hepatic miRNA signatures (Fig. 5 ). This could be especially useful for non-DNA-reactive hepatocarcinogens such as MON and Chl. Ac, which are difficult to identify based on their effects on liver pathology and clinical chemistry. In this context, the recent reports that circulating miRNAs could offer biomarkers of tissue injury and hepatocarcinogenesis (Laterza et al., 2009; Sukata et al., 2011) are important.
The DNA-damaging and mutagenic consequences of exposure to genotoxic hepatocarcinogens are well characterized, but the molecular events associated with nongenotoxic chemicals are not so well understood. To the best of our knowledge, this was the first study that has investigated in depth the effects of treatments with diverse genotoxic and nongenotoxic chemical hepatocarcinogens on the liver miRNAome. The data generated here support the hypothesis that hepatic miRNA profiles can facilitate an improved mechanistic understanding and the earlier prediction of chemical hepatocarcinogens, including nongenotoxic chemicals. Currently such predictions are very difficult.
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